HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

[Study on early fibrinolytic therapy to avoid acute myocardial infarction].

AbstractOBJECTIVE:
To investigate the frequency of aborted AMI and clinical characteristics of the patients received prompt fibrinolytic therapy.
METHODS:
1120 patients with AMI were divided into two groups, true AMI group and aborted AMI group. Aborted AMI was defined as maximal creatine kinase-MB < or = 2 x upper limit of normal coupled with the presence of resolution of chest pain and 50% of ST-segment deviation within 2 hours after onset of therapy. We compared some characteristic of two groups such as the fibrinolytic time after symptom onset and the frequency of aborted AMI.
RESULTS:
The reopening ratio of infarct was 80.5%. 7.1% of the patients escaped myocardial necrosis. Aborted AMI was highest frequency within the first hour (22.0%) than other time groups (P < 0.01); There were no significant differences in the frequency of Aborted AMI in UK group, SK group and rt-PA group (7.0%, 6.7%, 7.1%, P > 0.05); The rate of Killip III/IV, major arrhythmias, angina pectoris and mortality at 30 day in aborted AMI patients compared with those who had true AMI was 3.9% versus 17.1%, 18.0% versus 30.0%, 1.3% versus 8.0%, 0 versus 6.0%, respectively (P < 0.01).
CONCLUSION:
Prompt fibrinolytic therapy improved the likelihood of aborted AMI and clinical outcomes. The frequency of aborted AMI has no relationship with fibrinolytic drug, but closely related to the starting time of treatment from symptom onset.
AuthorsJi-gai Liu, Yu-cai Yao, Rui Xu, Wen-wei Xu, Wei Zhang, Rong-guang Kuang, Mei Gao
JournalZhonghua xin xue guan bing za zhi (Zhonghua Xin Xue Guan Bing Za Zhi) Vol. 33 Issue 9 Pg. 782-4 (Sep 2005) ISSN: 0253-3758 [Print] China
PMID16266450 (Publication Type: Controlled Clinical Trial, English Abstract, Journal Article)
Topics
  • Adult
  • Aged
  • Female
  • Humans
  • Male
  • Middle Aged
  • Myocardial Infarction (drug therapy, prevention & control)
  • Prognosis
  • Thrombolytic Therapy

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: